Crossmark

HGF/c-MET pathway in cancer: from molecular characterization to clinical evidence

Crossref DOI link: https://doi.org/10.1038/s41388-021-01863-w

Published Online: 2021-06-18

Published Print: 2021-07-15

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Fu, Jianjiang https://orcid.org/0000-0002-3952-9898
Su, Xiaorui https://orcid.org/0000-0001-5847-1794
Li, Zhihua https://orcid.org/0000-0003-0840-749X
Deng, Ling https://orcid.org/0000-0002-3195-3088
Liu, Xiawei https://orcid.org/0000-0001-9508-1832
Feng, Xuancheng https://orcid.org/0000-0002-8722-6306
Peng, Juan https://orcid.org/0000-0001-6308-3040
License Information

Text and Data Mining valid from 2021-06-18

Version of Record valid from 2021-06-18
More Information

Article History

Received: 5 May 2021

Revised: 17 May 2021

Accepted: 24 May 2021

First Online: 18 June 2021

Compliance with ethical standards

:

: The authors declare no competing interests.